Lipoglycopeptide

Lipoglycopeptides are a class of antibiotic that have lipophilic side-chains linked to glycopeptides. The class includes oritavancin, telavancin and dalbavancin.[1] [2]

In September 2009 the FDA approved Vibativ (telavancin) for complicated skin and skin structure infections (cSSSI) On May 23, 2014 FDA approved Dalvance (dalbavancin), an injectable drug, administered intravenously in two doses one week apart. On August 6, 2014 FDA approved Orbactiv (oritavancin), an injectable drug administered as a single dose to comprise a full course of therapy.

Telavancin is the most potent of the 3 against Clostridium spp.[3]

Approvals and clinical trials

Telavancin (once daily injection)[4] has completed 4 phase III trials.[5] and gained US FDA approval in September 2009 for complicated skin and skin structure infections (cSSSI).[6]

Oritavancin (once daily injection)[4] has completed phase II and phase III trials. [7][8][9] Oritavancin was approved by the FDA on August 6, 2014, and by the EMA mid-2015, for treatment of acute bacterial skin and skin structure infections (ABSSSI).[10][11]

Dalbavancin (once-weekly injection)[4] was undergoing a phase II trial, due to end in 2003.[12] The FDA approved Dalbavancin for use to treat MRSA infections in adults on May 23, 2014. Dalbavancin (Dalvance) is intended to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria like Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes. Dalbavancin is the first drug designated as a Qualified Infectious Disease Product (QIDP) to receive FDA approval. Under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act, dalbavancin was granted QIDP designation because it is an antibacterial or antifungal human drug intended to treat serious or life-threatening infections. As part of its QIDP designation, dalbavancin was given priority review, which provides an expedited review of the drug's application. dalbavancin's QIDP designation also qualifies it for an additional five years of marketing exclusivity to be added to certain exclusivity periods already provided by the Food, Drug and Cosmetic Act.

See also

References
  1. Kahne, Dan; Leimkuhler, Catherine; Lu, Wei; Walsh, Christopher (2005). "Glycopeptide and Lipoglycopeptide Antibiotics". Chemical Reviews. 105 (2): 425–448. doi:10.1021/cr030103a. PMID 15700951.
  2. "Fight Against Antimicrobial Resistance Recruiting New Agents". 1 Feb 2011.
  3. Zhanel, George G.; Calic, Divna; Schweizer, Frank; Zelenitsky, Sheryl; Adam, Heather; Lagacé-Wiens, Philippe R.S.; Rubinstein, Ethan; Gin, Alfred S.; et al. (2010-05-07). "New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin". Drugs. 70 (7): 859–886. doi:10.2165/11534440-000000000-00000. PMID 20426497. S2CID 207298905.
  4. Van Bambeke F. (August 2006). "Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy". Curr Opin Investig Drugs. 7 (8): 740–9. PMID 16955686.
  5. http://clinicaltrials.gov/ct2/results?term=telavancin&phase=2
  6. "Theravance and Astellas Announce FDA Approval of Vibativ (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections" (Press release). Theravance, Inc. and Astellas Pharma US, Inc. 2009-09-11. Retrieved September 16, 2009.
  7. http://clinicaltrials.gov/ct2/show/NCT00514527
  8. Kmeid J, Kanafani ZA (2015). "Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review". Core Evid. 10: 39–47. doi:10.2147/CE.S51284. PMC 4334198. PMID 25709561.
  9. Corey GR, Loutit J, Moeck G, Wikler M, Dudley MN, O'Riordan W, et al. (2018). "Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies". Antimicrob Agents Chemother. 62 (4): e01919–17. doi:10.1128/AAC.01919-17. PMC 5914007. PMID 29358292.
  10. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm408475.htm
  11. https://www.ema.europa.eu/en/medicines/human/EPAR/orbactiv
  12. http://clinicaltrials.gov/ct2/show/NCT00057369


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.